BEIGENE LTD-ADR (ONC) Stock Price, Quote, News and Summary
NASDAQ:ONC - Nasdaq - US07725L1026 - ADR
ONC Quote and Key Statistics
BEIGENE LTD-ADR
NASDAQ:ONC (1/16/2025, 8:00:02 PM)
After market: 205.34 0 (0%)205.34
+3.62 (+1.79%)
ONC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| Debt/Equity | 0.31 |
ONC Performance and Technical Analysis
ONC Ownership and Analysts
ONC Latest News and Analysis
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims up, manufacturing data beats expectations. S&P 500 & Nasdaq 100 gain 0.8%, regional banks suffer.
RBC Capital Thinks Oncolytics Biotech’s Stock is Going to Recover
A Wall Street analyst has provided a review for the Healthcare company yesterday, but retained the same rating on the stock. Analyst Douglas Miehm from RBC Capital rated Oncolytics Biotech (ONC – Research Report) a Buy, setting a C$10 price target. According to TipRanks.com, Miehm is ranked #4871 out of 5231 analysts. Read also: Tilray
Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech
In a new note to investors today, an analyst has provided a rating update for ...
The post Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech appeared first on Smarter Analyst.
Canaccord Genuity Issues a Buy Rating on Oncolytics Biotech
Today, an analyst has provided a rating update for the Healthcare company, Oncolytics Biotech (TSX: ...
The post Canaccord Genuity Issues a Buy Rating on Oncolytics Biotech appeared first on Smarter Analyst.
About ONC
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY
Employees: 10473
Company Website: https://www.beigene.com/
Investor Relations: https://ir.beigene.com
Phone: 13459494123
ONC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.16 | 306.95B | ||
| AMGN | AMGEN INC | 14.02 | 144.83B | ||
| GILD | GILEAD SCIENCES INC | 20.69 | 114.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 817.57 | 107.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.26 | 76.18B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.17B | ||
| NTRA | NATERA INC | N/A | 22.25B | ||
| BIIB | BIOGEN INC | 8.65 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.09 | 16.36B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 38.05 | 14.37B |